Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPhase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme
Cancer Chemotherapy and Pharmacology, 10/27/09
Metro1 G et al. – Concomitant radiotherapy–gemcitabine is active and well tolerated in newly diagnosed glioblastoma multiforme. Activity is observed both in tumors with methylated and unmethylated MGMT promoter.
Related Articles
Distribution, cellular localization, and therapeutic potential of the tumor-associated antigen Ku70/80 in glioblastoma multiforme
Journal of Neuro-Oncology, 10/28/09
Relevance Score: 88%
Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment
Clinical Cancer Research, 10/01/09
Relevance Score: 88%
Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes
Cancer, 11/12/09
Relevance Score: 87%
Antiglioma Immunological Memory in Response to Conditional Cytotoxic/Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression
Clinical Cancer Research, 10/06/09
Relevance Score: 87%
Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme
Journal of Neuro-Oncology, 10/01/09
Relevance Score: 87%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Propylene Glycol Accumulation in Critically Ill Patients Receiving Continuous Intravenous Lorazepam Infusions
Annals of Pharmacotherapy, 11/25/09
Effect of cilnidipine vs losartan on cerebral blood flow in hypertensive patients with a history of ischemic stroke: a randomized controlled trial
Acta Neurologica Scandinavica, 11/25/09
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09
Sponsor
Article Search
Sponsor